BloodPressureHeartMeds.Net

Adamis receives patents for APC-200 prostate cancer drug in South Africa, Singapore

August 13, 2017

Reactive oxygen species (ROS) are constantly created and eliminated in the body, and play important roles in a variety of normal biochemical functions and abnormal pathological processes. Levels of ROS such as hydrogen peroxide, superoxide, and free hydroxyl radicals have been described to be elevated in prostate epithelial cells and a link between ROS, the associated oxidative stress and prostate cancer development and progression has been suggested. Recently, it was furthermore found that androgen receptor signaling may be involved in raising ROS levels in prostate cancer cells. APC-200 inhibits ROS formation in prostate cancer cells, thereby helping to block not only tissue inflammation but also androgen-induced oxidative stress. Animal studies have documented not only APC-200's ability to inhibit chronic inflammation, but have also found that APC-200 can significantly delay prostate cancer progression and increase survival among diseased animals. To date, APC-200 is thought to have a favorable safety profile.

APC-200 has previously received the National Cancer Institute's (NCI) multi-year, multi-million dollar RAPID Award (Rapid Access to Preventative Intervention Development). Each year, this award is given by the NCI Division of Cancer Prevention, under the RAPID Program (now called PREVENT), to what it believes are the most promising new preventative/therapeutic anti-cancer drugs.

Dr. Dennis J. Carlo, President and CEO of Adamis, stated, "Since APC-200 could end up being a very important drug for the treatment of early prostate cancer, we have put together a substantial patent portfolio covering most of the major countries throughout the world. Being able to delay the progression between castration-sensitive and castration-resistant prostate cancer could very well equate to adding years of survival time to patients. APC-200 will be our next prostate cancer drug to enter clinical trials."

Source: Adamis Pharmaceuticals Corporation